文献速递系统性红斑狼疮

活动性狼疮肾炎免疫抑制治疗后肾脏抗体分泌细胞的分子特征

Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy.
PubMed 文献 · Arthritis Rheumatol · 2021-07-16

该研究对活检证实的活动性狼疮肾炎患者肾脏及尿液抗体分泌细胞(ASC)进行表征,发现未治疗患者肾脏CD138+ ASC数量与低eGFR及小管间质损伤相关,难治性患者肾脏ASC主要为长寿命浆细胞,6个月时尿液ASC存在与治疗失败相关。

要点

  • 未治疗活动性狼疮肾炎患者肾脏CD138+ ASC数量与低eGFR和小管间质损伤相关。
  • 难治性狼疮肾炎患者肾脏ASC以长寿命浆细胞为主,不同于未治疗者的浆母细胞特征。
  • 诱导治疗6个月时尿液ASC存在与治疗失败相关。

核心结论

  • 结果提示针对ASC的治疗可能用于难治性狼疮肾炎。

研究设计与样本

  • 纳入活检证实的活动性狼疮肾炎患者,对肾活检样本行抗CD138染色以显示ASC。
  • 对新鲜活检样本分选ASC行单细胞基因表达谱分析,采用多重逆转录聚合酶链反应检测浆母细胞向长寿命浆细胞成熟的基因集。
  • 对未治疗狼疮肾炎患者诊断时及诱导治疗6个月前瞻性随访时量化尿液ASC。

主要发现

  • 46例未治疗狼疮肾炎患者肾脏CD138+ ASC数量与低eGFR及小管间质损伤相关。
  • 3例未治疗患者大多数肾脏ASC呈浆母细胞分子特征。
  • 4例难治性狼疮肾炎患者肾脏ASC主要为长寿命浆细胞,转录谱与2例健康供者骨髓相似。
  • 未治疗活动性狼疮肾炎患者中可检测到部分具有浆母细胞特征的尿液ASC。
  • 诱导治疗6个月时尿液ASC存在与治疗失败相关。

临床怎么用

  • 肾脏ASC分子特征或有助于识别难治性狼疮肾炎并指导ASC靶向治疗探索。
  • 诱导治疗6个月时检测尿液ASC或有助于评估治疗失败风险。

局限性

  • 单细胞基因表达谱分析仅基于3例未治疗患者和4例难治性患者的肾脏ASC。
  • 长寿命浆细胞转录谱比较仅基于2例健康供者骨髓。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to characterize kidney and urine antibody-secreting cells (ASCs) from patients with active lupus nephritis, before and after induction therapy. METHODS: We included patients with biopsy-proven active lupus nephritis and performed anti-CD138 staining of kidney biopsy samples to visualize ASCs. We performed single-cell gene expression profiling on sorted ASCs from fresh biopsy samples using multiplex reverse transcriptase-polymerase chain reaction. We used a gene set that allowed for the study of ASC maturation from plasmablasts to long-lived plasma cells. We quantified urine ASCs from untreated patients with lupus nephritis at diagnosis and after 6 months of prospective follow-up during induction therapy. RESULTS: The number of kidney CD138+ ASCs in 46 untreated patients with lupus nephritis was correlated with a low estimated glomerular filtration rate and with tubulointerstitial damage. Most kidney ASCs from 3 untreated patients had a plasmablast molecular signature; in contrast, in 4 patients with refractory lupus nephritis, the kidney ASCs were mainly long-lived plasma cells, representing an ASC transcriptional profile similar to that in the bone marrow of 2 healthy donors. Some urine ASCs with a plasmablast signature were detected in patients with untreated active lupus nephritis. The presence of urine ASCs at 6 months was associated with treatment failure. CONCLUSION: Our results suggest potential for ASC-directed therapy in refractory lupus nephritis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Crickx E, Tamirou F, Huscenot T, et al. Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy. Arthritis Rheumatol. 2021. PMID: 33645886. doi:10.1002/art.41703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。